Study: Lotion Shows Efficacy in Treating Hyperkeratotic Plaque Psoriasis

Key Takeaways

• HP/TAZ lotion was superior to vehicle in reducing both plaque elevation and scaling in patients with hyperkeratotic psoriasis.

• The researchers reported consistent across multiple subgroups, and no safety or tolerability issues were reported.

HP/TAZ lotion significantly improved hyperkeratotic psoriatic plaques in subgroups, according to recent data from a post hoc analysis of phase 3 trials.

The authors of the post hoc analysis pooled data from two eight-week, vehicle-controlled phase 3 trials with a subsequent four-week follow-up. The authors examined two primary subgroup analyses. In Analysis 1, researchers gave separate evaluations to participants with either severe plaque elevation or severe scaling at baseline. In Analysis 2, the researchers focused patients with moderate-to-severe elevation and an Investigator’s Global Assessment (IGA) of 3 or 4. Clinical endpoints included a ≥2-grade improvement in plaque elevation or scaling and safety measures.

At week 8, the results showed HP/TAZ outperforming vehicle in all study groups. In Analysis 1, patients with severe plaque elevation and scaling saw statistically significant success rates (P < .05). In Analysis 2, improvements in elevation and scaling were also statistically significant (P ≤ .001).

Tolerability improved from baseline by almost 50% (46%) in all groups. Adverse events were comparable between the HP/TAZ and vehicle.

"HP/TAZ was efficacious and well tolerated for treating hyperkeratotic plaques," the authors wrote. The study was published in the Journal of Drugs in Dermatology.

Source: Tanghetti E, et al. Journal of Drugs in Dermatology. 2025. doi:10.36849/JDD.8720R1